日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Discovery of Zharp1-163 as a dual inhibitor of ferroptosis and necroptosis for the treatment of inflammatory disorders and kidney injury.

发现 Zharp1-163 可作为铁死亡和坏死性凋亡的双重抑制剂,用于治疗炎症性疾病和肾损伤

Ji Yuting, Du Shujing, Li Jingjing, Ma Haikuo, Wang Xinhui, Hao Yongjin, Li Zhanhui, Lu Haohao, Liu Hao, Yang Chengkui, Zhang Xiaohu, He Sudan

A novel RIPK1 inhibitor reduces GVHD in mice via a nonimmunosuppressive mechanism that restores intestinal homeostasis

一种新型RIPK1抑制剂通过非免疫抑制机制降低小鼠的移植物抗宿主病(GVHD),该机制可恢复肠道稳态。

Yu, Xiaoliang; Ma, Haikuo; Li, Bohan; Ji, Yuting; Du, Yayun; Liu, Siying; Li, Zhanhui; Hao, Yongjin; Tian, Sheng; Zhao, Cong; Du, Qian; Jin, Zhongqin; Zhu, Xueming; Tian, Yuanyuan; Chen, Xin; Sun, Xue; Yang, Chengkui; Zhu, Fang; Ju, Jie; Zheng, Yunjing; Zhang, Wei; Wang, Jingrui; Yang, Tao; Wang, Xinhui; Li, Jingjing; Xu, Xiangping; Du, Shujing; Lu, Haohao; Ma, Feng; Zhang, Haibing; Zhang, Yi; Zhang, Xiaohu; Hu, Shaoyan; He, Sudan

Optimization of 6-heterocyclic-2-(1H-pyrazol-1-yl)-N-(pyridin-2-yl)pyrimidin-4-amine as potent adenosine A2A receptor antagonists for the treatment of Parkinson's disease.

优化 6-杂环-2-(1H-吡唑-1-基)-N-(吡啶-2-基)嘧啶-4-胺作为治疗帕金森病的强效腺苷 A2A 受体拮抗剂

Zheng Jiyue, Yang Zhaohui, Li Xuan, Li Linlang, Ma Haikuo, Wang Meiyu, Zhang Hongjian, Zhen Xuechu, Zhang Xiaohu